Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new ...

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition strengthens its position in the U.S. market, with significant market share ...

Biocon plans IPO for biosimilars business by March 2026 Biosimilars are similar and relatively affordable versions of high-priced and complex biologics drugs used to treat illnesses such as cancer ...

HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a ...